China News Agency, Beijing, January 17 (Ma Shuaisha) Since the implementation of the "Class B and B Control" for new crown virus infection, Chinese officials have continued to promote the development and marketing of new crown virus treatment drugs, and severely cracked down on the illegal production and sale of fake new crown virus infection treatment drugs Criminal behavior; the local government further optimized the medical insurance reimbursement policy for new crown infection, provided new crown virus antibody testing, met the public's medical needs, and guaranteed the quality and safety of medicines.

　　A drug for the treatment of severe cases of the new crown was approved, the official cracked down on the illegal and criminal activities of manufacturing and selling counterfeit and inferior drugs

　　According to news from the State Drug Administration on the 16th, recently, the State Drug Administration approved the listing of Tocilizumab Injection (trade name: Serili) declared by Bio-Thera Bio-Pharmaceutical Co., Ltd.

The drug is the first biosimilar tocilizumab injection approved in China.

　　It is reported that at present, tocilizumab injection is included in the "Diagnosis and Treatment Program for New Coronavirus Infection (Trial Version 10)" and "Diagnosis and Treatment Program for Severe Cases of New Coronavirus Infection (Trial Version 4)". It can be tried if the level of IL-6 is significantly increased.

　　In addition, in response to the recent clues of illegal sales of drugs for the treatment of new coronavirus infection with unknown sources in the market, the local drug regulatory department and the local public security department have jointly enforced the law and destroyed some criminal gangs and dens. Paxlovid (Nimatevir Tablets/Ritonavir Tablets Combination Package) and unapproved imported drugs, etc.

　　After inspection, some of the seized products did not contain effective pharmaceutical ingredients or were illegally added with other pharmaceutical ingredients, suspected of violating the provisions of Article 141 of the Criminal Law on the crime of selling counterfeit medicines.

At present, the case is being handled by the public security department according to law.

　　Shenzhen implements full guarantee for hospitalization expenses of new crown patients Wuhan provides new crown virus antibody detection

　　The Shenzhen Municipal Medical Security Bureau recently issued a notice to optimize the medical security related policies for the treatment expenses of patients infected with the new coronavirus.

This includes the full guarantee of the hospitalization expenses of patients infected with the new coronavirus. This policy is calculated based on the admission time of patients infected with the new coronavirus and will be implemented until March 31, 2023.

　　In addition, Shenzhen has also improved the reimbursement level of outpatient and emergency expenses in primary medical institutions.

From January 8 to March 31, the medical expenses related to the treatment of new coronavirus infection within the scope of the medical insurance catalog incurred by the insured patients with new coronavirus infection and suspected symptoms in outpatient and emergency departments of designated medical institutions of second-level and below medical insurance shall be covered by the basic medical insurance. The critical illness pooling fund pays 85%, and there is no minimum payment line and no ceiling line. Individual self-payment expenses can be paid by the balance of the insured person's personal account according to regulations.

　　The Wuhan Disease Control and Prevention Medical Service Center has recently launched a new coronavirus nucleic acid antibody level detection service to scientifically evaluate the immune status of the new crown recovery and the resistance to secondary infection for the public.

The Wuhan Center for Disease Control and Prevention stated that the detection of new coronavirus antibodies can be used as a basis for auxiliary diagnosis of new coronavirus infection, and can also be used as a basis for recommendation of new coronavirus vaccination time and vaccination plan.

　　As the global COVID-19 epidemic enters the stage of normalized prevention and control, the immigration offices of many countries require a negative test report for the new coronavirus nucleic acid. The English version of the new coronavirus nucleic acid test report has become one of the necessary valid documents for entry-exit and visa processing.

In order to meet the needs of citizens for studying abroad, doing business, visiting relatives, immigration, tourism, etc., the Wuhan Center for Disease Control and Prevention Medical Services also provides Chinese and English versions of the new coronavirus nucleic acid test report to citizens in need.

Since January 8, immigration management agencies across the country have inspected 501,000 entry-exit personnel on a daily basis.

　　According to news from the National Immigration Administration on the 17th, since January 8, 2023, when the "Class B and B Control" of the new crown virus infection was officially implemented, the national immigration management agencies have inspected an average of 501,000 entry-exit personnel per day, an increase of 48.2% compared with before the implementation. It is 26.3% of that before the epidemic; the average daily acceptance of entry and exit documents is 341,000, an increase of 129.4% compared with that before the implementation, which is 54.5% of that before the epidemic.

　　Li Tong, chief physician of the Department of Infectious Diseases at Beijing You'an Hospital, once suggested that traveling abroad during the Spring Festival may encounter different strains from domestic ones. If there is no "positive" experience, the risk of infection when traveling abroad will increase.

If you get sick in a foreign country, you should also consider medical treatment and medication issues. You must be prepared, such as masks, disinfectant wipes and other epidemic prevention materials. It is best to understand the local medical treatment process.

　　Recently, foreign reports of the detection of the "Deltacoron" XAY.2 strain have attracted attention.

Li Tong once said that at present, it has not been found that the XAY.2 strain has become the main epidemic strain in a certain country or region, increasing the rate of severe illness.

Theoretically speaking, the characteristics of the recombinant virus may become more uncertain. Once it becomes popular, it means that it has a stronger immune escape ability, and it needs to continue to pay attention.

(Finish)